Papa et al. carried out a phase I clinical trial enrolling patients with very advanced heavily pre-treated and chemo-refractory HNSCC and administered in them an autologous CD28-based CAR-T cell approach: the T4 immunotherapy [45]. Here, CD28 is linked to head and neck squamous cell carcinoma.